Alcresta to Present at the 34th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2016 – Alcresta Pharmaceuticals, a specialty pharmaceutical company focused on developing innovative enzyme-based products for gastrointestinal and rare disease, today announced that John Tucker, Chief Executive Officer of Alcresta, will provide a corporate presentation at the 34th Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT (10:30 p.m. ET), on Thursday, January 14, 2016, in the Elizabethan D room at the Westin St. Francis Hotel in San Francisco.

About Alcresta® Pharmaceuticals

Alcresta is a specialty pharmaceutical company dedicated to developing and commercializing novel enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency, which results in malabsorption common in cystic fibrosis, digestive cancers, premature birth and other serious diseases. The company’s lead product, Relizorb™, recently approved by the FDA, is designed to reliably and efficiently improve the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA) for those using enteral tube feeding. The importance of long-chain polyunsaturated fatty acids like omega-3 is well documented across the full spectrum of patient care from infants to adults and individuals battling acute conditions or chronic diseases. The company’s platform is supported by the Alcresta team’s extensive experience in pharmaceutical and nutritional product development. Based in Newton, Mass., the company is backed by top-tier venture investors Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures. For more information, please visit www.alcresta.com.

Alcresta Contact:
Robert Gallotto, President
Alcresta Pharmaceuticals, Inc.
617-431-3586

Relizorb is a trademark of Alcresta Pharmaceuticals, Inc. All rights reserved 2015.